Top

Published in:

Open Access 01-11-2018 | Original Article

Chemotherapy-induced apoptosis, autophagy and cell cycle arrest are key drivers of synergy in chemo-immunotherapy of epithelial ovarian cancer

Authors: John Wahba, Marina Natoli, Lynsey M. Whilding, Ana C. Parente-Pereira, Youngrock Jung, Stefania Zona, Eric W.-F. Lam, J. Richard Smith, John Maher, Sadaf Ghaem-Maghami

Published in: Cancer Immunology, Immunotherapy | Issue 11/2018

Abstract

Epithelial ovarian cancer (EOC) is the most lethal of all gynecological malignancies in the UK. Recent evidence has shown that there is potential for immunotherapies to be successful in treating this cancer. We have previously shown the effective application of combinations of traditional chemotherapy and CAR (chimeric antigen receptor) T cell immunotherapy in in vitro and in vivo models of EOC. Platinum-based chemotherapy synergizes with ErbB-targeted CAR T cells (named T4), significantly reducing tumor burden in mice. Here, we show that paclitaxel synergizes with T4 as well, and look into the mechanisms behind the effectiveness of chemo-immunotherapy in our system. Impairment of caspase activity using pan-caspase inhibitor Z-VAD reveals this chemotherapy-induced apoptotic pathway as an essential factor in driving synergy. Mannose-6-phosphate receptor-mediated autophagy and the arrest of cell cycle in G2/M are also shown to be induced by chemotherapy and significantly contributing to the synergy. Increased expression of PD-1 on T4 CAR T cells occurred when these were in culture with ovarian tumor cells; on the other hand, EOC cell lines showed increased PD-L1 expression following chemotherapy treatment. These findings provided a rationale to look into testing PD-1 blockade in combination with paclitaxel and T4 immunotherapy. Combination of these three agents in mice resulted in significant reduction of tumor burden, compared to each treatment alone. In conclusion, the mechanism driving synergy in chemo-immunotherapy of EOC is multifactorial. A deeper understanding of such process is needed to better design combination therapies and carefully stratify patients.

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12):2893–2917. https://doi.org/10.1002/ijc.25516 CrossRefPubMed

Berrino F, De Angelis R, Sant M, Rosso S, Bielska-Lasota M, Coebergh JW, Santaquilani M, group EW (2007) Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol 8(9):773–783. https://doi.org/10.1016/S1470-2045(07)70245-0 CrossRefPubMed

Ozols RF (2000) Management of advanced ovarian cancer consensus summary. Advanced Ovarian Cancer Consensus Faculty. Semin Oncol 27(3 Suppl 7):47–49PubMed

Greenlee RT, Hill-Harmon MB, Murray T, Thun M (2001) Cancer statistics, 2001. CA Cancer J Clin 51(1):15–36CrossRefPubMed

Liang XJ, Mukherjee S, Shen DW, Maxfield FR, Gottesman MM (2006) Endocytic recycling compartments altered in cisplatin-resistant cancer cells. Cancer Res 66(4):2346–2353. https://doi.org/10.1158/0008-5472.CAN-05-3436 CrossRefPubMedPubMedCentral

Godwin AK, Meister A, O’Dwyer PJ, Huang CS, Hamilton TC, Anderson ME (1992) High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 89(7):3070–3074CrossRefPubMedPubMedCentral

Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E (1992) ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 84(19):1512–1517CrossRefPubMed

Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R (2000) Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 60(21):6039–6044PubMed

Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME (2008) Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8(4):299–308. https://doi.org/10.1038/nrc2355 CrossRefPubMedPubMedCentral

10.

Parente-Pereira AC, Whilding LM, Brewig N, van der Stegen SJ, Davies DM, Wilkie S, van Schalkwyk MC, Ghaem-Maghami S, Maher J (2013) Synergistic chemoimmunotherapy of epithelial ovarian cancer using ErbB-retargeted T cells combined with carboplatin. J Immunol 191(5):2437–2445. https://doi.org/10.4049/jimmunol.1301119 CrossRefPubMed

11.

John LB, Devaud C, Duong CP, Yong CS, Beavis PA, Haynes NM, Chow MT, Smyth MJ, Kershaw MH, Darcy PK (2013) Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res 19(20):5636–5646. https://doi.org/10.1158/1078-0432.CCR-13-0458 CrossRefPubMed

12.

Davies DM, Foster J, Van Der Stegen SJ, Parente-Pereira AC, Chiapero-Stanke L, Delinassios GJ, Burbridge SE, Kao V, Liu Z, Bosshard-Carter L, Van Schalkwyk MC, Box C, Eccles SA, Mather SJ, Wilkie S, Maher J (2012) Flexible targeting of ErbB dimers that drive tumorigenesis using genetically engineered T cells. Mol Med 18:565–576. https://doi.org/10.2119/molmed.2011.00493 CrossRefPubMedPubMedCentral

13.

Siwak DR, Carey M, Hennessy BT, Nguyen CT, McGahren Murray MJ, Nolden L, Mills GB (2010) Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. J Oncol 2010:568938. https://doi.org/10.1155/2010/568938 CrossRefPubMed

14.

Anglesio MS, Kommoss S, Tolcher MC, Clarke B, Galletta L, Porter H, Damaraju S, Fereday S, Winterhoff BJ, Kalloger SE, Senz J, Yang W, Steed H, Allo G, Ferguson S, Shaw P, Teoman A, Garcia JJ, Schoolmeester JK, Bakkum-Gamez J, Tinker AV, Bowtell DD, Huntsman DG, Gilks CB, McAlpine JN (2013) Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J Pathol 229(1):111–120. https://doi.org/10.1002/path.4088 CrossRefPubMed

15.

Ocana A, Vera-Badillo F, Seruga B, Templeton A, Pandiella A, Amir E (2013) HER3 overexpression and survival in solid tumors: a meta-analysis. J Natl Cancer Inst 105(4):266–273. https://doi.org/10.1093/jnci/djs501 CrossRefPubMed

16.

Paatero I, Lassus H, Junttila TT, Kaskinen M, Butzow R, Elenius K (2013) CYT-1 isoform of ErbB4 is an independent prognostic factor in serous ovarian cancer and selectively promotes ovarian cancer cell growth in vitro. Gynecol Oncol 129(1):179–187. https://doi.org/10.1016/j.ygyno.2012.12.044 CrossRefPubMed

17.

Nars MS, Kaneno R (2013) Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy. Int J Cancer 132(11):2471–2478. https://doi.org/10.1002/ijc.27801 CrossRefPubMed

18.

Pushkarev VM, Starenki DV, Saenko VA, Pushkarev VV, Kovzun OI, Tronko MD, Popadiuk ID, Yamashita S (2008) Differential effects of low and high doses of Taxol in anaplastic thyroid cancer cells: possible implication of the Pin1 prolyl isomerase. Exp Oncol 30(3):190–194PubMed

19.

Yeung TK, Germond C, Chen X, Wang Z (1999) The mode of action of taxol: apoptosis at low concentration and necrosis at high concentration. Biochem Biophys Res Commun 263(2):398–404. https://doi.org/10.1006/bbrc.1999.1375 CrossRefPubMed

20.

Furness AJ, Vargas FA, Peggs KS, Quezada SA (2014) Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies. Trends Immunol 35(7):290–298. https://doi.org/10.1016/j.it.2014.05.002 CrossRefPubMed

21.

Hansen JM, Coleman RL, Sood AK (2016) Targeting the tumour microenvironment in ovarian cancer. Eur J Cancer 56:131–143. https://doi.org/10.1016/j.ejca.2015.12.016 CrossRefPubMedPubMedCentral

22.

Topalian SL, Drake CG, Pardoll DM (2015) Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27(4):450–461. https://doi.org/10.1016/j.ccell.2015.03.001 CrossRefPubMedPubMedCentral

23.

Hamanishi J, Mandai M, Konishi I (2016) Immune checkpoint inhibition in ovarian cancer. Int Immunol 28(7):339–348. https://doi.org/10.1093/intimm/dxw020 CrossRefPubMed

24.

Mitchell MJ, Webster J, Chung A, Guimaraes PP, Khan OF, Langer R (2017) Polymeric mechanical amplifiers of immune cytokine-mediated apoptosis. Nat Commun 8:14179. https://doi.org/10.1038/ncomms14179 CrossRefPubMedPubMedCentral

25.

Wu YT, Tan HL, Shui G, Bauvy C, Huang Q, Wenk MR, Ong CN, Codogno P, Shen HM (2010) Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class I and III phosphoinositide 3-kinase. J Biol Chem 285(14):10850–10861. https://doi.org/10.1074/jbc.M109.080796 CrossRefPubMedPubMedCentral

26.

Zhou J, Li G, Zheng Y, Shen HM, Hu X, Ming QL, Huang C, Li P, Gao N (2015) A novel autophagy/mitophagy inhibitor liensinine sensitizes breast cancer cells to chemotherapy through DNM1L-mediated mitochondrial fission. Autophagy 11(8):1259–1279. https://doi.org/10.1080/15548627.2015.1056970 CrossRefPubMedPubMedCentral

27.

Ramakrishnan R, Huang C, Cho HI, Lloyd M, Johnson J, Ren X, Altiok S, Sullivan D, Weber J, Celis E, Gabrilovich DI (2012) Autophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immunotherapy. Cancer Res 72(21):5483–5493. https://doi.org/10.1158/0008-5472.CAN-12-2236 CrossRefPubMedPubMedCentral

28.

Rodnina MV, Savelsbergh A, Matassova NB, Katunin VI, Semenkov YP, Wintermeyer W (1999) Thiostrepton inhibits the turnover but not the GTPase of elongation factor G on the ribosome. Proc Natl Acad Sci USA 96(17):9586–9590CrossRefPubMedPubMedCentral

29.

Kwok JM, Myatt SS, Marson CM, Coombes RC, Constantinidou D, Lam EW (2008) Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression. Mol Cancer Ther 7(7):2022–2032. https://doi.org/10.1158/1535-7163.MCT-08-0188 CrossRefPubMed

Title: Chemotherapy-induced apoptosis, autophagy and cell cycle arrest are key drivers of synergy in chemo-immunotherapy of epithelial ovarian cancer
Authors: John Wahba
Marina Natoli
Lynsey M. Whilding
Ana C. Parente-Pereira
Youngrock Jung
Stefania Zona
Eric W.-F. Lam
J. Richard Smith
John Maher
Sadaf Ghaem-Maghami
Publication date: 01-11-2018
Publisher: Springer Berlin Heidelberg
Published in: Cancer Immunology, Immunotherapy / Issue 11/2018
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-018-2199-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2018

PD-1/PD-L1 co-inhibition shapes anticancer T cell immunodominance: facing the consequences of an immunological ménage à trois

TCR repertoire profiling of tumors, adjacent normal tissues, and peripheral blood predicts survival in nasopharyngeal carcinoma

Beta-glucan-induced inflammatory monocytes mediate antitumor efficacy in the murine lung

Circulating CD8+ T-cell repertoires reveal the biological characteristics of tumors and clinical responses to chemotherapy in breast cancer patients

Increased Tim-3+ T cells in PBMCs during nivolumab therapy correlate with responses and prognosis of advanced esophageal squamous cell carcinoma patients

Molecular subgroups and B7-H4 expression levels predict responses to dendritic cell vaccines in glioblastoma: an exploratory randomized phase II clinical trial

Keynote webinar | Spotlight on antibody–drug conjugates in cancer